TrialReader


Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2

NCT03012217 — Completed, 1612 participants, BioFire Diagnostics, LLC

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2 (RP2)

RegistryNCT03012217, acronym RP2
StatusCompleted
Study typeObservational
Enrollment1612 (Actual)
SponsorBioFire Diagnostics, LLC (Industry)
ConditionsUpper Resp Tract Infection
InterventionsObservational Study (Other)
Datesstart 2016-09-01, primary completion 2016-12-01, completion 2016-12-01, first posted 2017-01-06, last updated 2017-01-12
Locations3 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Upper Resp Tract Infection All trials of Observational Study

-Summary

This is a performance study to test the sensitivity and specificity of the BioFire FilmArray Respiratory Panel (RP) 2. The purpose of this study is to prospectively collect and test residual NPS specimens and generate performance data to support regulatory classification of the FilmArray RP2 as an in vitro diagnostic (IVD) in the US, European Union (EU), Canada, and other regions.

Expand all sections  ·  Collapse all

+Detailed description

The FilmArray Respiratory Panel 2 (RP2) is an automated sample-to-answer PCR-based diagnostic for the identification of common upper respiratory viral and bacterial pathogens in nasopharyngeal swab (NPS) specimens collected in viral transport media (VTM). The purpose of this study is to prospectively collect and test residual NPS specimens and generate performance data to support regulatory classification of the FilmArray RP2 as an in vitro diagnostic (IVD) in the US, European Union (EU), Canada, and other regions.

Clinical performance evaluations will be initiated at sites in the US and/or EU during the 2016/2017 respiratory illness season, approximately September through December.Prior to performing the prospective clinical evaluation, each participating site will have the necessary Institutional Review Board (IRB) reviews (or equivalent for non-U.S. sites).

Specimens for inclusion in this study will be residual, de-identified NPS collected in VTM leftover from clinician-ordered respiratory pathogen testing.

Comparator testing will be performed using de-identified specimen aliquots at a central reference laboratory.

This study is funded by BioFire Diagnostics, LLC. The FilmArray device conforms to the requirements of the European Union In Vitro Diagnostic Directive (IVDD). This study was designed such that every precaution has been taken to protect the health and safety of patients, users, and other persons.

+Arms and interventions

ArmTypeInterventionsDescription
Specimens that meet inclusion criteriaOther: Observational Study
  • Observational Study (Other)

+Outcome measures

Primary outcomes

  • sensitivity and specificity of device [3 months]

+Eligibility

Sex: All

Inclusion Criteria:

* Specimen is residual NPS in VTM left over from standard of care testing under clinician order for respiratory pathogen analysis
* Specimen has been held at appropriate temperature
* Sufficient volume remaining after standard of care testing and available for use in the study

Exclusion criteria:

* Specimen other than NPS in VTM (e.g. nasopharyngeal aspirate, anterior or midturbinate swab, oropharyngeal swab, NPS collected in medium other than VTM)
* Specimen cannot be tested within the defined storage parameters
* Insufficient specimen volume for testing

+Locations (3)

FacilityCityCountryStatus
Loyola University Medical CenterMaywood, IllinoisUnited States
Nationwide Children's HospitalColumbus, OhioUnited States
Primary Children's HospitalSalt Lake City, UtahUnited States

My Notes